## ORIGINAL RESEARCH



# Computational evaluation and experimental verification of antibacterial and antioxidant activity of 7-hydroxy-3pyrazolyl-4*H*-chromen-4-ones and their *o*-glucosides: identification of pharmacophore sites

Javed Sheikh · Kishor Hatzade · Ammar Bader · Usama Shaheen · Thomas Sander · Taibi Ben Hadda

Received: 7 January 2013 / Accepted: 6 May 2013 © Springer Science+Business Media New York 2013

**Abstract** This paper reports the computational evaluation and experimental verification of 7-hydroxy-3-(1-phenyl-3aryl-1*H*-pyrazol-5-yl)-4*H*-chromen-4-ones **3** and their o- $\beta$ -D-glucopyranosides **5** for their antimicrobial and antioxidant activity. The prepared compounds were tested against various Gram-positive and Gram-negative bacteria species. Some of the synthesized compounds have shown potential antimicrobial and antioxidant activity. This POM bioinformatic study could greatly help to pharmacomodulate the potential antibiotics and antioxidants.

**Keywords** Chromones  $\cdot$  Pyrazoles  $\cdot o - \beta$ -D-Glucosides  $\cdot$  Virtual screening  $\cdot$  Petra, Osiris, and molinspiration (POM)  $\cdot$  Chemoinformatics

#### Introduction

Flavonoids constitute one of the most active classes of compounds possessing diverse pharmacological and

J. Sheikh (⊠) · K. Hatzade Department of Chemistry, Dhote Bandhu Science College, Gondia 441614, India e-mail: sheikhchemie@gmail.com

A. Bader · U. Shaheen Department of Pharmacognosy, Faculty of Pharmacy, Umm Al-Qura University, Mecca 21955, Saudi Arabia

T. Sander Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, 4123 Allschwil, Switzerland

T. Ben Hadda Laboratoire Chimie Matériaux, FSO, Université Mohammed 1ER, 6000 Oujda, Morocco e-mail: taibi.ben.hadda@gmail.com microbial activity (Billeret et al., 1993; Cingolani et al., 1969). The widespread flavonoids act as various functional secondary metabolites in plants. Literature survey reveals that chromones show anticancer (Atassi et al., 1985; Birt et al., 2001; López-Lázaro, 2002; Pouget et al., 2001; Zheng et al., 2003), anti-HIV (Yu et al., 2004), and antioxidant properties (Burda and Oleszek, 2001; Rackova et al., 2005). Pyrazoles are quite popular in the field of medicine and agro chemistry. A number of pyrazole derivatives have been reported to possess interesting biological activities like anti-inflammatory (Bernard et al., 1986), antimicrobial and antiprotozoal (Bochis et al., 1986). In addition, pyrazole is found widely as a core structure in a large variety of compounds that exhibit important biological activity (Pevarello et al., 2005). Many organic compounds containing carbohydrate exhibit a wide variety of biological and therapeutic properties (Dwek, 1996). Another group of carbohydrate exhibiting potential therapeutic uses is nucleoside analogs. Nucleosides are also glycosides that occur in nucleic acids. Several O-, N-, and C-glycosides have been isolated from other natural sources (The Merck Index, 1989). These compounds have a wide range of biological relevance including antibacterial, antifungal, antiviral, and antitumoral activities. As a result, the formation of the glycosidic linkage continues to be a predominant theme in carbohydrate chemistry (Boons, 1996). Carbohydrates play important roles in a variety of biological processes, such as signaling, cell-cell communications, molecular and cellular targeting (Sears and Wong, 1999).

In view of these pertinent observations and in continuation to our work (Ingle *et al.*, 2007) on chromone-based heterocycles, it was considered to synthesize chemical entities incorporating three active pharmacophores namely chromone, pyrazole, and glucose moiety in a single molecular framework so as to get biologically active





compounds (Hatzade *et al.*, 2008). Herein, we report the computational evaluation of chromones/pyrazoles glucoside using Petra/Osiris/Molinspiration (POM) approach and their experimental verification (Fig. 1).

## **Results and discussion**

#### Synthesis of compounds 3–5

7-Hydoxy-3-formyl chromen-4*H*-one **1** on condensation with substituted acetophenones in the presence of piperidine in dry alcohol affords 7-hydroxy-3-(3-oxo-3-arylprop-1-enyl)-4*H*-chromen-4-ones **2** which on cyclization with phenyl hydrazine hydrochloride leads to the formation of 7-hydroxy-3-(1-phenyl-3-aryl-1*H*-pyrazol-5-yl)-4*H*-chromen-4-ones **3**. 7-o- $\beta$ -D-Glucopyranosyloxy-3-(1-phenyl-3aryl-1*H*-pyrazol-5-yl)-4*H*-chromen-4-ones **5** have been synthesized by the reaction of 2,3,4,6-tetra-o-acetyl- $\alpha$ -Dglucopyranosyl bromide with potassium salt of **3** followed by deacetylation with Zn(CH<sub>3</sub>COO)<sub>2</sub> in absolute methanol. All the compounds described have been previously prepared and well characterized by NMR, Mass and IR spectroscopic methods (Hatzade *et al.*, 2008) (Scheme 1).

#### **Biological activity**

Compounds **3a–3i** and **5a–5i** were evaluated for various biological screening programs. The various screening programs carried out includes the in vitro antibacterial activity against *Escherichia coli, Klebisilla aerogens, Staphyllococcus aureus*, and *Bacillus substilis* and in vitro

antifungal activity against *A. niger* and *C. albicans* fungi using the cup plate diffusion method (Vagdevi *et al.*, 2001) by measuring the inhibition zones in mm. The comparative studies of the aglycones and glucosides have been observed by using standard ciprofloxacin, sulfacetamide for bacteria and gentamycin, clotrimazole (100 µg/mL) for fungi. The test compounds were dissolved in DMSO at a concentration of 100 µg/mL. Most of the compounds exhibited mild to moderate antibacterial activity as well as antifungal activity against all the microbes tested (Table 1). Similarly in vitro free radical scavenging activities of glucosides were evaluated by DPPH assay method and most of the compounds were found to be active at 1 mg/mL concentration. Percentage scavenging of DPPH radical was calculated using the formula:

% Scavenging of DPPH =  $[(Control - Test)/Control] \times 100.$ 

Theoretical calculations of molecular properties of **3a–3i** and **5a–5i** 

The aqueous and/or ethanol extraction of flavonoids have often been used in traditional medicine, and also have, therefore, been studied for their antitumor, antioxidant, antiviral, anti-algal, antimicrobial, cytotoxic, and antiinflammatory, significant hepatoprotective and cardiovascular activity without any criteria of selection.

In continuation of our first POM analyses (Ben Hadda *et al.*, 2012), on Natural Flavonoids (Fig. 2), as potential antibacterial/antiviral drugs, the present study furnishes an overview of the 20 synthetic flavonoids and antifungal/ antibacterial activity of their metabolite species. Here, on the basis of POM analyses, a simple, economic, quick and

Scheme 1 Synthetic protocol for compounds 3–5 (Hatzade *et al.*, 2008)



efficient bioinformatic platform, it now becomes easy and possible to predict and optimize the flavonoids bioactivity.

#### Petra calculations

During the past 15 years, our group investigated the potential pharmacophores of various heterocycles for their possible antiviral and/or antibacterial activity and verified them further with Petra/Osiris/Molinspiration (POM) analyses (Chohan *et al.*, 2010; Jarrahpour *et al.*, 2010, 2011; Masand *et al.*, 2012; Parvez *et al.*, 2010a, b; Rauf *et al.*, 2011; Sheikh *et al.*, 2011; Sheikh and Hadda, 2012). On the basis of the new findings, we can conclude that series **3a–3i** and **5a–5i** engage in opening/closing of B ring showing that **3–5** act as prodrugs and, in the presence of bacteria, can furnish active metabolites bearing keto and two hydroxyl groups containing a potential antibacterial/antiviral/antifungal O,O,O-pharmacophore site (Fig. 3).

For antibacterial activity, the compound should possess  $(X^{\delta^-}-Y^{\delta^+})$  pharmacophore site and also it was hypothesized that the difference in charge between *X* and *Y* of the same dipolar pharmacophoric site should facilitate the inhibition of bacteria more than viruses. In contrast to antibacterial agent, the antiviral drug should have  $(X^{\delta^-}-Y^{\delta^-})$  pharmacophore site with respect of some architectural parameters (dihedral angle = 0–10° and distance  $dx-y = 3-3.5 \text{ A}^\circ$ ) (Chohan *et al.*, 2010; Jarrahpour *et al.*, 2010, 2011; Masand *et al.*, 2012; Parvez *et al.*, 2010a, b; Rauf *et al.*, 2011; Sheikh *et al.*, 2011; Sheikh and Hadda, 2012). POM analyses confirm the existence of a combined antibacterial/antifungal pharmacophore site (Fig. 4).

#### Osiris calculations

The remarkably well-behaved mutagenicity of divers synthetic molecules classified in database of Celeron Company of Swiss can be used to quantify the role played by various

Table 1 Antimicrobial and antioxidant activity of compounds 3a-i and 5a-i

Zone of inhibition	(mm) (Activity	index)std

Zone of inhibition (mm) (Activity index) <sup>std</sup>									
Sr. No.	Antibacterial	activity	Antifungal act	Antifungal activity					
	Gram-positiv	e	Gram-negativ	ve	C. albicans	A. niger	activity		
	S. aureus	B. substilis	E. coli	K. aerogens			DPPH		
<b>3</b> a	20 (0.58) <sup>a</sup>	17 (0.59) <sup>a</sup>	17 (0.49) <sup>a</sup>	22 (1.00) <sup>a</sup>	30 (1.43) <sup>a</sup>	19 (0.76) <sup>a</sup>	86.56		
	$(0.65)^{\rm b}$	$(0.65)^{\rm b}$	$(0.59)^{b}$	$(1.04)^{b}$	$(1.30)^{b}$	$(0.79)^{b}$	$(0.88)^{a}$		
3b	21 (0.62) <sup>a</sup>	19 (0.66) <sup>a</sup>	19 (0.54) <sup>a</sup>	19 (0.86) <sup>a</sup>	27 (1.29) <sup>a</sup>	$20 (0.80)^{a}$	88.73		
	$(0.68)^{b}$	$(0.73)^{\rm b}$	$(0.66)^{b}$	$(0.90)^{b}$	$(1.17)^{b}$	$(0.83)^{b}$	$(0.90)^{a}$		
3c	20 (0.58) <sup>a</sup>	19 (0.66) <sup>a</sup>	22 (0.63) <sup>a</sup>	20 (0.91) <sup>a</sup>	23 (1.09) <sup>a</sup>	16 (0.64) <sup>a</sup>	86.10		
	$(0.65)^{\rm b}$	$(0.73)^{\rm b}$	$(0.76)^{b}$	$(0.95)^{\rm b}$	$(1.00)^{b}$	$(0.66)^{b}$	$(0.86)^{a}$		
3d	21 (0.62) <sup>a</sup>	18 (0.62) <sup>a</sup>	17 (0.49) <sup>a</sup>	17 (0.77) <sup>a</sup>	23 (1.09) <sup>a</sup>	$18 (0.72)^{a}$	79.87		
	$(0.68)^{b}$	$(0.69)^{\rm b}$	$(0.59)^{b}$	$(0.81)^{b}$	$(1.00)^{b}$	$(0.75)^{b}$	$(0.81)^{a}$		
3e	$24 (0.71)^{a}$	$20 (0.69)^{a}$	$20 (0.57)^{a}$	19 (0.86) <sup>a</sup>	25 (1.19) <sup>a</sup>	$20 (0.80)^{a}$	80.56		
	(0.77) <sup>b</sup>	(0.77) <sup>b</sup>	(0.69) <sup>b</sup>	(0.90) <sup>b</sup>	$(1.07)^{b}$	(0.83) <sup>b</sup>	$(0.87)^{a}$		
3f	$23 (0.68)^{a}$	$17 (0.59)^{a}$	$21 (0.60)^{a}$	$24 (1.09)^{a}$	$23 (1.09)^{a}$	$22 (0.88)^{a}$	86.13		
	(0.74) <sup>b</sup>	$(0.65)^{\rm b}$	(0.72) <sup>b</sup>	(1.14) <sup>b</sup>	$(1.00)^{b}$	(0.92) <sup>b</sup>	$(0.86)^{a}$		
3g	$23 (0.68)^{a}$	$22 (0.76)^{a}$	$20 (0.57)^{a}$	$22(1.00)^{a}$	$29 (1.38)^{a}$	$19 (0.76)^{a}$	85.56		
. 9	$(0.74)^{b}$	$(0.85)^{\rm b}$	$(0.69)^{b}$	$(1.04)^{b}$	$(1.26)^{b}$	$(0.79)^{b}$	$(0.87)^{a}$		
3h	$(0.65)^{a}$	$(0.62)^{a}$	$16 (0.46)^{a}$	$(0.77)^{a}$	$(0.20)^{a}$	$16 (0.64)^{a}$	88.75		
-	$(0.71)^{b}$	$(0.69)^{b}$	$(0.55)^{b}$	$(0.81)^{b}$	$(0.83)^{b}$	$(0.66)^{b}$	$(0.90)^{a}$		
3i	$(0.74)^{a}$	$(0.05)^{a}$	$(0.00)^{a}$	$(0.01)^{a}$	$(0.02)^{a}$	$(0.00)^{a}$	86.45		
01	$(0.81)^{b}$	$(0.77)^{b}$	$(0.72)^{b}$	$(0.90)^{b}$	$(0.87)^{b}$	$(0.83)^{b}$	$(0.88)^{a}$		
5a	$(0.01)^{a}$	$(0.77)^{a}$	$(0.72)^{a}$	$(0.90)^{a}$	$(0.07)^{a}$	$(0.03)^{a}$	88 68		
eu	$(0.90)^{b}$	$(0.77)^{b}$	$(0.62)^{b}$	$(1, 14)^{b}$	$(1.48)^{b}$	$(0.88)^{b}$	$(0.90)^{a}$		
5h	$(0.90)^{a}$	$(0.77)^{a}$	$(0.02)^{a}$	(1.14) 20 (0.91) <sup>a</sup>	$(1.40)^{a}$	$(0.00)^{a}$	90.76		
50	$(0.84)^{b}$	$(0.60)^{b}$	$(0.60)^{b}$	$(0.95)^{b}$	$(1.26)^{b}$	$(0.88)^{b}$	$(0.93)^{a}$		
50	(0.0+) 22 (0.65) <sup>a</sup>	$(0.09)^{a}$	$(0.09)^{a}$	$(0.93)^{a}$	(1.20) 22 (1.04) <sup>a</sup>	(0.00) 18 (0.72) <sup>a</sup>	(0.93)		
50	$(0.71)^{b}$	22 (0.70) (0.85) <sup>b</sup>	$(0.83)^{b}$	$(1.04)^{b}$	$(0.06)^{b}$	$(0.75)^{b}$	$(0.80)^{a}$		
54	(0.71)	(0.03)	(0.83) 18 (0.51) <sup>a</sup>	(1.04) 10 (0.86) <sup>a</sup>	(0.90)	(0.73) 10 (0.76) <sup>a</sup>	(0.89)		
Ju	$(0.81)^{b}$	21 (0.72) (0.81)	$(0.62)^{b}$	$(0.00)^{b}$	$(1.00)^{b}$	$(0.70)^{b}$	$(0.82)^{a}$		
<b>F</b>	(0.01)	$24 (0.82)^{a}$	(0.02)	(0.90)	(1.09)	(0.79)	(0.82)		
56	$(1.00)^{b}$	24(0.83)	$(0.76)^{b}$	$(1.04)^{b}$	$(1.17)^{b}$	$(0.02)^{b}$	82.43		
<b>7</b> 6	(1.00)	(0.92)	(0.70)	(1.04)	(1.17)	(0.92)	(0.84)		
51	33 (0.97)	$22(0.76)^{\circ}$	$20(0.57)^{*}$	27 (1.23) <sup>2</sup>	25 (1.19)"	23 (0.92)	88.73		
-	$(1.06)^{2}$	(0.85) <sup>2</sup>	$(0.69)^{-1}$	(1.29) <sup>2</sup>	$(1.07)^{-1}$	(0.96) <sup>-</sup>	(0.90)-		
5g	$30(0.88)^{\circ}$	27 (0.93) <sup>a</sup>	19 (0.54)"	24 (1.09) <sup>a</sup>	30 (1.43)"	22 (0.88) <sup>a</sup>	86.12		
-	$(0.97)^{\circ}$	(1.04)	$(0.66)^{6}$	(1.14)	$(1.30)^{6}$	(0.92)	(0.88)"		
5h	25 (0.74) <sup>a</sup>	$19 (0.66)^{a}$	$17 (0.49)^{a}$	17 (0.77) <sup>a</sup>	20 (0.95) <sup>a</sup>	16 (0.64) <sup>a</sup>	91.65		
	(0.81) <sup>6</sup>	(0.73)	(0.59) <sup>6</sup>	(0.81)	(0.87)	(0.66) <sup>6</sup>	(0.93) <sup>a</sup>		
5i	31 (0.91) <sup>a</sup>	$23 (0.79)^{a}$	23 (0.66) <sup>a</sup>	20 (0.91) <sup>a</sup>	23 (1.09) <sup>a</sup>	21 (0.84) <sup>a</sup>	86.56		
	(1.00) <sup>b</sup>	$(0.88)^{0}$	$(0.79)^{\rm b}$	(0.95) <sup>b</sup>	$(1.00)^{\rm b}$	$(0.88)^{\rm p}$	$(0.88)^{\rm a}$		
Std. 1	34	29	35	22	21	25	98.03		
Std. 2	31	26	29	21	23	24			

(Activity index) = Inhibition zone of the sample/Inhibition zone of the standard. For antibacterial activity: Std. 1 = ciprofloxacin and Std. 2 = sulfacetamide, For antifungal activity: Std. 1 = gentamycin and Std. 2 = clotrimazole. For antioxidant activity: Std. 1 = ascorbic Acid

<sup>a</sup> Activity index against Std. 1

<sup>b</sup> Activity index against Std. 2



organic groups in promoting or interfering with the way a drug can associate with DNA. The Osiris calculations are tabulated in Tables 2 and 3. Toxicity risks (mutagenicity, tumorogenicity, irritation, reproduction) and physicochemical properties (CLogP, solubility, drug-likeness, and drug-score) of prodrugs 3–5 and their metabolites 3'-5'were calculated by the methodology developed by Osiris. The toxicity risk predictor locates fragments within a molecule, which indicate a potential toxicity risk. Toxicity risk alerts are an indication that the drawn structure may be harmful concerning the risk category specified. From the data evaluated in Tables 2 and 3 it is obvious that, majority of structures are supposed to be non-mutagenic, non-irritating with no reproductive effects when run through the mutagenicity assessment system in comparison with the standard drug. Low hydrophilicities and, therefore, high log P values may cause poor absorption or permeation. It has been shown that for compounds to have a reasonable probability of good absorption, their  $\log P$  value must not

be greater than 5.0. On this basis, all the prodrugs 3-5 and their metabolites 3'-5' possessed log *P* values in the acceptable range.

The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. Typically, a low solubility goes along with a bad absorption and, therefore, the general aim is to avoid poorly soluble compounds. Our estimated  $\log S$  value is a unit stripped logarithm (base 10) of a compound's solubility in mol/L. There are more than 80 % of the drugs in the market that have an (estimated)  $\log S$  value greater than -4. In case of compounds 3-5 and 3'-5', values of log S are around (-4)-(-5). Further, Tables 2 and 3 show drug-likeness of compounds 3-5 and 3'-5' which is in the comparable zone with that of standard drugs used for comparison. The reported compounds 3-5 and 3'-5'(except 3h, 5h, 3h', and 5h') showed no toxicity risk and have good drug-score as compared with the two standard drugs used.

Compd.	MW		Toxicity	y risk		Osiris calculations					
		MUT	TUMO	IRRI	REP	CLP	S	D-L	D-S		
<b>3</b> a	380					3.51	-4.86	-0.83	0.41		
3b	414					4.12	-5.59	0.26	0.39		
3c	458					4.21	-5.69	-2.63	0.24		
3d	394					3.83	-5.20	-2.06	0.32		
3e	410					3.41	-4.87	-0.31	0.44		
3f	448					4.74	-6.33	0.44	0.31		
3g	448					4.74	-6.33	-046	0.27		
3h	425					3.38	-5.32	-5.93	0.22		
3i	425					3.38	-5.32	-10.80	0.28		
5a	542					1.40	-4.74	-3.89	0.27		
5b	576					2.01	-5.48	-3.01	0.23		
5c	620					2.10	-5.58	-5.60	0.20		
5d	556					1.72	-5.09	-5.04	0.24		
5e	572					1.30	-4.76	-3.32	0.26		
5f	610					2.63	-6.21	-2.90	0.19		
5g	610					2.63	-6.21	-3.57	0.18		
5h	587					1.27	-5.20	-8.81	0.18		
5i	587					1.27	-5.20	-13.82	0.23		
Ciprof	330					1.63	-3.42	2.33	0.65		
Sulpha	214					0.17	-1.53	5.46	0.35		
Genta	477					-4.03	-1.18	4.88	0.77		
Clotri	344					4.97	-7.72	-0.10	0.28		
Ascorb	176					-2.23	-0.35	0.02	0.44		

Table 2Osiris calculations ofcompounds3a-3iand5a-5i

MUT mutagenic, TUMO tumorigenic, IRRI irritant, REP reproductive effective, CLP CLogP, S solubility, DL druglikness, DS drug-score, Ciprof ciprofloxacin, Sulpha sulfacetamide, Genta gentamycin, Clotri clotrimazole, Ascorb ascorbic acid

# Molinspiration calculations

This method is very robust and is able to process practically all organic and most organometallic molecules.

🖄 Springer

Molecular Polar Surface Area TPSA is calculated based on the corresponding methodology as a sum of fragment contributions (Chohan *et al.*, 2010; Jarrahpour *et al.*, 2010, 2011; Parvez *et al.*, 2010a, b; Rauf *et al.*, 2011; Sheikh Table 3 Osiris calculations of Compd. MW **Toxicity risk Osiris calculations** compounds 3a'-3i' and 5a'-5i' resulting from opening of ring B MUT TUMO IRRI REP CLP S D-L D-S of flavonoids/prodrugs 3a-3i 3a′ 400 3.02 -4.24 0.56 0.57 and 5a-5i 3b' 434 3.64 -4.981.67 0.53 478 3.72 3c' -5.08-1.260.32 3d' 414 3.34 -4.59-0.700.43 3e' 430 2.92 -4.261.06 0.59 3f' 468 4.25 -5.711.95 0.41 3g' 468 4.25 -5.710.93 0.38 3h' 445 2.89 -4.70-4.570.25 3i' 445 2.89 -4.70-9.540.31 5a' 561 0.91 -4.13 -2.610.30 5b' 596 1.53 -4.86 -1.730.27 5c' 640 1.61 -4.96 -4.33 0.22 5d′ 576 1.23 -4.47 -3.77 0.26 5e' 592 -4.15 -2.050.29 0.81 MUT mutagenic, TUMO 5f′ 630 2.14 -5.60 -1.61 0.23 tumorigenic, IRRI irritant, REP 2.14 5g' 630 -5.6 -2.290.21 reproductive effective, CLP 5h' 607 0.78 -4.59 -7.57 0.19 CLogP, S solubility, DL 5i′ 605 1.42 -5.05-11.15 0.13 druglikness, DS drug-score

Table 4 Molinspiration calculations of compounds 3a-3i and 5a-5i

Compd.	R	Molinspiration calculations						Drug-likeness					
		TPSA	NONI	NV	nrotb	VOL	GPCR	ICM	KI	NRL	PI	EI	
3a	Н	68	1	0	3	332	-0.14	-0.58	-0.06	-0.03	-0.67	-0.03	
3b	4-Cl	68	1	0	3	346	-0.14	-0.57	-0.08	-0.05	-0.69	-0.06	
3c	4-Br	68	1	1	3	350	-0.22	-0.62	-0.10	-0.13	-0.75	-0.09	
3d	4-CH <sub>3</sub>	68	1	0	3	349	-0.17	-0.63	-0.10	-0.06	-0.70	-0.08	
3e	4-OCH <sub>3</sub>	77	1	0	4	358	-0.17	-0.59	-0.08	-0.05	-0.67	-0.07	
3f	2,5-Cl <sub>2</sub>	68	1	1	3	359	-0.10	-0.54	-0.06	-0.04	-0.65	-0.08	
3g	3,5-Cl <sub>2</sub>	68	1	1	3	359	-0.13	-0.55	-0.07	-0.03	-0.68	-0.05	
3h	3-NO <sub>2</sub>	114	1	0	4	355	-0.25	-0.58	-0.15	-0.11	-0.73	-0.11	
3i	$4-NO_2$	114	1	0	4	355	-0.25	-0.57	-0.17	-0.12	-0.73	-0.12	
5a	Н	147	4	1	6	464	-0.06	-0.64	-0.15	-0.13	-0.43	0.08	
5b	4-Cl	147	4	1	6	478	-0.08	-0.71	-0.20	-0.20	-0.45	0.01	
5c	4-Br	147	4	1	6	482	-0.14	-0.75	-0.22	-0.25	-0.50	-0.01	
5d	4-CH <sub>3</sub>	147	4	1	6	481	-0.11	-0.75	-0.22	-0.20	-0.46	-0.01	
5e	4-OCH <sub>3</sub>	157	4	2	7	490	-0.12	-0.81	-0.25	-0.26	-0.44	-0.04	
5f	2,5-Cl <sub>2</sub>	147	4	1	6	491	-0.09	-0.78	-0.25	-0.25	-0.43	-0.06	
5g	3,5-Cl <sub>2</sub>	147	4	1	6	491	-0.10	-0.79	-0.25	-0.24	-0.45	-0.04	
5h	3-NO <sub>2</sub>	199	4	2	7	483	-0.27	-0.93	-0.40	-0.36	-0.51	-0.27	
5i	$4-NO_2$	199	4	2	7	483	-0.27	-0.93	-0.42	-0.37	-0.51	-0.28	
Std. 1	-	70	2	0	3	290	0.36	0.09	-0.05	0.01	0.14	0.18	
Std. 2	_	89	3	0	2	175	-0.46	-0.48	-0.70	-1.28	-0.36	-0.12	
Std. 3	_	200	11	2	7	451	0.34	0.19	0.18	-0.06	0.66	0.46	
Std. 4	-	18	0	1	4	310	0.17	0.30	0.14	-0.21	-0.13	0.42	

TPSA total polar surface area, VOL volume, ONI OH–NH interaction, NV number of violation, GPCR GPCR ligand, ICM ion channel modulator, KI kinase inhibitor, NRL nuclear receptor ligand, Std. 1 ciprofloxacin, Std. 2 sulfacetamide, Std. 3 gentamycin, Std. 4 clotrimazole

Compd.	R	Molinspiration calculations						Drug-likeness					
		TPSA	NONI	NV	nrotb	VOL	GPCR	ICM	KI	NRL	PI	EI	
3a'	Н	96	3	0	6	356	0.02	-0.21	-0.06	0.21	-0.17	0.06	
3b′	4-Cl	96	3	0	6	370	0.02	-0.21	-0.08	0.18	-0.20	0.03	
3c′	4-Br	96	3	0	6	374	-0.06	-0.27	-0.01	0.11	-0.26	-0.01	
3d′	4-CH <sub>3</sub>	96	3	0	6	372	-0.01	-0.26	-0.10	0.18	-0.22	0.01	
3e′	4-OCH <sub>3</sub>	105	3	0	7	382	-0.01	-0.25	-0.09	0.17	-0.20	0.02	
3f′	2,5-Cl <sub>2</sub>	96	3	0	6	383	0.05	-0.20	-0.06	0.18	-0.18	0.00	
<b>3</b> g′	3,5-Cl <sub>2</sub>	96	3	0	6	383	0.03	-0.21	-0.07	0.20	-0.21	0.03	
3h′	3-NO <sub>2</sub>	141	3	0	7	379	-0.10	-0.24	-0.15	0.11	-0.28	-0.03	
3i′	$4-NO_2$	141	3	0	7	379	-0.10	-0.24	-0.17	0.10	-0.27	-0.04	
5a′	Н	175	6	3	9	488	0.03	-0.44	-0.20	0.00	-0.10	0.09	
5b′	4-Cl	175	6	3	9	502	0.00	-0.52	-0.26	-0.07	-0.12	0.01	
5c′	4-Br	174	6	3	9	506	-0.06	-0.56	-0.28	-0.13	-0.17	-0.01	
5d′	4-CH <sub>3</sub>	175	6	3	9	505	-0.03	-0.56	-0.28	-0.08	-0.13	-0.00	
5e′	4-OCH <sub>3</sub>	184	6	3	10	514	-0.06	-0.64	-0.32	-0.16	-0.13	-0.06	
5f′	2,5-Cl <sub>2</sub>	175	6	3	9	515	-0.02	-0.61	-0.32	-0.14	-0.12	-0.08	
5g′	3,5-Cl <sub>2</sub>	175	6	3	9	515	-0.04	-0.62	-0.32	-0.153	-0.14	-0.05	
5h′	3-NO <sub>2</sub>	221	6	3	10	511	-0.18	-0.75	-0.46	-0.28	-0.21	-0.18	
5i′	$4-NO_2$	221	6	3	10	512	-0.18	-0.75	-0.48	-0.28	-0.21	-0.19	
Std. 1	-	70	2	0	3	290	0.36	0.09	-0.05	0.01	0.14	0.18	
Std. 2	-	89	3	0	2	175	-0.46	-0.48	-0.70	-1.28	-0.36	-0.12	
Std. 3	-	200	11	2	7	451	0.34	0.19	0.18	-0.06	0.66	0.46	
Std. 4	-	18	0	1	4	310	0.17	0.30	0.14	-0.21	-0.13	0.42	
Std. 5	-	107	4	0	2	140	-0.53	-0.24	-1.01	-1.01	-0.81	0.20	

Table 5 Molinspiration calculations of compounds 3a'-3i' and 5a'-5i' resulting from opening of ring B of flavonoids/prodrugs 3a-3i and 5a-5i, respectively

*TPSA* total polar surface area, *VOL* volume, *ONI* OH–NH interaction, *NV* number of violation, *GPCR* GPCR ligand, *ICM* ion channel modulator, *KI* kinase inhibitor, *NRL* nuclear receptor ligand, *Std. 1* ciprofloxacin, *Std. 2* sulfacetamide, *Std. 3* gentamycin, *Std. 4* clotrimazole, *Std. 5* ascorbic acid

*et al.*, 2011; Sheikh and Hadda, 2012). O-centered polar fragments are considered. PSA has been shown to be a very good descriptor characterizing drug absorption, including intestinal absorption, bioavailability, Caco-2 permeability, and blood–brain barrier penetration. CLogP (octanol/water partition coefficient) is calculated by the methodology developed by Molinspiration as a sum of fragment-based contributions and correction factors (Tables 4 and 5).

## Conclusion

The tested compounds are flavonoid analogs substituted at different positions and were virtually evaluated by POM for their in vitro antimicrobial activity against the pathogen bacteria. The preliminary structure–activity relationship (SAR) analysis suggested that the introduction of appropriate di-substituted pyrazole ring into position 3 of chromen-4-one ring enhanced antibacterial activities of these compounds.

**Acknowledgments** The authors are sincerely thankful to the Principal, Dhote Bandhu Science College, Gondia for providing necessary help. Prof. Dr. J. Sheikh and Prof. Dr. T. B. Hadda would like to thank ACTELION; the Biopharmaceutical Company of Swiss, for the molecular properties calculations.

## References

- Atassi G, Briet P, Berthelon JJ, Colonge F (1985) Synthesis and antitumor-activity of some 8- substituted-4-oxo-4H-1-benzopyrans. Eur J Med Chem 20:393–402
- Ben Hadda T, Fergoug T, Warad I, Masand V, Sheikh J (2013) POM as a quick bioinformatic platform to select flavonoids and their metabolites as potential and efficient HIV-1 integrase inhibitors. Res Chem Intermed 39:1227–1244
- Bernard M, Hulley E, MoLenda H, Stochla K, Wrzecino U (1986) Beta-(4-pyrazol)acrylic and propionic acids and their antiinflammatory activity. Pharmazie 41(8):560–562
- Billeret D, Blondeau D, Sliwa H (1993) Convenient synthesis of 5-azacoumarins. J Heterocycl Chem 30:671–674
- Birt DF, Hendrich S, Wang W (2001) Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90:157–177

- Bochis RJ, Dybas RA, Rogers EF (1986) Antiprotozoal 3-amino or substituted amino pyrazoles. US Pat 4(622):330
- Boons GJ (1996) Strategies in oligosaccharide synthesis. Tetrahedron 52:1095–1121
- Burda S, Oleszek W (2001) Antioxidant and antiradical activities of flavonoids. J Agric Food Chem 49:2774–2779
- Chohan ZH, Youssoufi MH, Jarrahpour A, Hadda TB (2010) Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulphonamide derivatives. Eur J Med Chem 45(3):1189–1199
- Cingolani GM, Gualtieri F, Pigiri M (1969) Researches in the field of antiviral compounds. Mannich Bases of 3-hydroxycoumarin. J Med Chem 12:531–532
- Dwek RA (1996) Glycobiology: toward understanding the function of sugars. Chem Rev 96:683–720
- Hatzade KM, Taile VS, Gaidhane PK, Haldar AGM, Ingle VN (2008) Synthesis and biological activities of new hydroxy-3-pyrazolyl-4*H*-chromen-4-ones and their *o*-glucosides. Indian J Chem B 47:1260–1270
- Ingle VN, Hatzade KM, Taile VS, Gaidhane PK, Kharche ST (2007) Synthesis of O-β-D-glucopyranosides of 7-hydroxy-3-(imidazol-2-yl)-4H-chromen-4-ones. J Carbohydr Chem 26(2):107–123
- Jarrahpour A, Motamedifar M, Zareil M, Youssoufi MH, Mimouni M, Chohan ZH, Hadda TB (2010) Petra, Osiris and Molinspiration together as a guide in drug design: predictions and correlation structure/antibacterial activity relationships of new N-sulfonyl monocyclic β-lactams (Part II). Phosphorus Sulfur Silicon Relat Elem 185:491–497
- Jarrahpour A, Fathi J, Mimouni M, Hadda TB, Sheikh J, Chohan ZH (2011) Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. Med Chem Res 19(7):1–7
- López-Lázaro M (2002) Flavonoids as anticancer agents: structureactivity relationship study. Curr Med Chem 2:691–714
- Marchand C, Johnson AA, Semenova E, Pommier Y (2006) Mechanisms and inhibition of HIV integration. Drug Discov Today Dis Mech 3:253
- Masand VH, Mahajan DT, Patil KN, Ben Hadda T, Jawarkar RD, Thakur SD, Rastija V (2012) CoMSIA and POM analyses of anti-malarial activity of synthetic prodiginines. Bioorg Med Chem Lett 22:4827–4835
- Mizoribin. In: The Merck Index, 11th edn. Merck and Co, Inc, Rahway, 1989, p 980
- Parvez A, Jyotsna M, Youssoufi MH, Hadda TB (2010a) Theoretical calculations and experimental verification of the antibacterial potential of some monocyclic beta-lactames containing two

synergetic buried antibacterial pharmacophore sites. Phosphorus Sulfur Silicon Relat Elem 7:1500–1510

- Parvez A, Meshram J, Tiwari V, Sheikh J, Dongre R, Youssoufi MH, Hadda TB (2010b) Pharmacophores modeling in terms of prediction of theoretical physicochemical properties and verification by experimental correlations of novel coumarin derivatives produced via Betti's protocol. Eur J Med Chem 45(9):4370–4378
- Pevarello P, Brasca MG, Orsini P, Traquandi G, Longo A, Nesi M, Orzi F, Piutti C, Sansonna P, Varasi M, Cameron A, Vulpetti A, Roletto F, Alzani R, Cinmei M, Albanese C, Pastori W, Marsiglio A, Pesenti E, Fiorentini F, Bischoff JR, Mercurio C (2005) 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. J Med Chem 48:2944–2956
- Pouget C, Lauthier F, Simon A, Fagnere C, Basly J-P, Delage C, Chulia A-J (2001) Flavonoids: structural requirements for antiproliferative activity on breast cancer cells. Bioorg Med Chem Lett 11:3095–3097
- Rackova L, Firakova S, Kostalova D, Stefek M, Sturdik E, Majekova M (2005) Oxidation of liposomal membrane suppressed by flavonoids: quantitative structure-activity relationship. Bioorg Med Chem 13:6477–6484
- Rauf A, Ahmed F, Qureshi AM, Khan AA, Qadir MI, Choudhary MI, Chohan ZH, Youssoufi MH, Hadda TB (2011) Synthesis and urease inhibition studies of barbituric and thiobarbituric acid derived sulphonamides. J Chin Chem Soc 58(4):1–10
- Sears P, Wong CH (1999) Carbohydrate mimetics: a new strategy for tackling the problem of carbohydrate mediated biological recognition. Angew Chem Int Ed 38:2300–2324
- Sheikh J, Hadda BT (2013) Antibacterial, antifungal and antioxidant activity of some new water-soluble beta-diketones. Med Chem Res 22:964–975
- Sheikh J, Parvez A, Juneja H, Ingle V, Chohan ZH, Youssoufi MH, Hadda TB (2011) Synthesis, biopharmaceutical characterization, antimicrobial and antioxidant activities of 1-(4'-O-β-D-glucopyranosyloxy-2'-hydroxyphenyl)-3-aryl-propane-1,3-diones. Eur J Med Chem 46:1390–1399
- Vagdevi HM, Latha KP, Vaidya VP, Vijay Kumar ML, Pai KSR (2001) Synthesis and pharmacological screening of some novel naphtha [2,1-b] furo-pyrazoline isoxazoles and isoxazolines. Indian J Pharm Sci 63:286–291
- Yu D, Chen CH, Brossi A, Lee KH (2004) Camphanoyl-20,20dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents. J Med Chem 47:4072–4082
- Zheng X, Meng WD, Xu YY, Cao JG, Qing FL (2003) Synthesis and anticancer effect of chrysin derivatives. Bioorg Med Chem Lett 13:881–884